Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
Barinthus Biotherapeutics plc - American Depositary Shares (BRNS)
Company Research
Source: GlobeNewswire
Single ascending dose data readout for VTP-1000 expected before the end of 2025Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to strengthen and diversify the pipeline and broaden the Company’s base of high caliber institutional investors. GERMANTOWN, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results for the quarter ended September 30, 2025, and provided an overview of the Company’s corporate developments. "The proposed combination of Barinthus Bio and Clywedog represents an important step toward building a stronger, more resilient company, with several expected near-term catalysts.” said Bill Enright, Chief Exec
Show less
Read more
Impact Snapshot
Event Time:
BRNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BRNS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BRNS alerts
High impacting Barinthus Biotherapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BRNS
News
- $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITBPR Newswire
- Barinthus Biotherapeutics (NASDAQ:BRNS) had its price target raised by analysts at HC Wainwright from $3.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus TherapeuticsPR Newswire
- SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of ShareholdersPR Newswire
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Barinthus Biotherapeutics plc (NASDAQ: BRNS)GlobeNewswire
BRNS
Earnings
- 5/7/25 - Miss
BRNS
Sec Filings
- 11/7/25 - Form 10-Q
- 11/7/25 - Form 8-K
- BRNS's page on the SEC website